You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Locally Recurrent Breast Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer, Recurrent Trial in Meldola (Partial breast re-irradiation)

Not yet recruiting
  • Breast Cancer
  • Recurrent
  • Partial breast re-irradiation
  • Meldola, Forlì Cesena, Italy
    UO Radioterapia, IRST IRCCS
Mar 6, 2023

Metastatic Breast Cancer Trial (SKB264, Eribulin, Capecitabine)

Not yet recruiting
  • Metastatic Breast Cancer
  • (no location specified)
Oct 7, 2023

Locally Advanced or Recurrent Metastatic HER-2 Negative Breast Cancer Trial in Shanghai (BL-B01D1, SI-B003)

Not yet recruiting
  • Locally Advanced or Recurrent Metastatic HER-2 Negative Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Sep 12, 2023

Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation Trial in Shanghai (Everolimus, Investigator's Choice of

Not yet recruiting
  • Triple Negative Breast Cancer
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jul 25, 2023

Breast Cancer Female, Breast Tumor Female Trial in United States (SV-BR-1-GM, INCMGA00012, Low dose cyclophosphamide)

Recruiting
  • Breast Cancer
  • +3 more
  • SV-BR-1-GM
  • +3 more
  • Newport Beach, California
  • +9 more
Dec 8, 2022

Metastatic Breast Cancer Trial in Shanghai (Sitravatinib, Tislelizumab, Nab-paclitaxel)

Recruiting
  • Metastatic Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer
Jul 31, 2022

Triple Negative Breast Cancer (TNBC) Trial (Pembrolizumab, Nab-paclitaxel, Paclitaxel)

Active, not recruiting
Has Results
  • Triple Negative Breast Cancer (TNBC)
  • Pembrolizumab
  • +5 more
  • (no location specified)
Jul 15, 2022

Locally Recurrent/Metastatic Triple Negative Breast Cancer Trial in United States (radiation, drug, procedure)

Recruiting
  • Locally Recurrent/Metastatic Triple Negative Breast Cancer
  • external beam radiation therapy
  • +2 more
  • Basking Ridge, New Jersey
  • +6 more
Aug 8, 2022

Triple Negative Breast Cancer Trial (SKB264)

Not yet recruiting
  • Triple Negative Breast Cancer
  • (no location specified)
Apr 20, 2022

Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma Trial in United States (Laboratory

Active, not recruiting
Has Results
  • Locally Advanced Breast Carcinoma
  • +7 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Duarte, California
  • +3 more
Jan 31, 2023

Male Breast Cancer, Recurrent Melanoma, Stage IV Breast Cancer Trial in Columbus (propranolol HCl, Correlative Studies)

Completed
  • Male Breast Cancer
  • +7 more
  • propranolol hydrochloride
  • Correlative Studies
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Dec 4, 2022

Triple-negative Breast Cancer Trial in Changsha, Nanjing (SKB264, KL-A167)

Not yet recruiting
  • Triple-negative Breast Cancer
  • Changsha, Hunan, China
  • +1 more
Jun 30, 2022

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Locally Advanced Solid Tumor Trial in New Brunswick, New York (Laboratory Biomarker

Recruiting
  • BRCA1 Gene Mutation
  • +19 more
  • Laboratory Biomarker Analysis
  • Pembrolizumab
  • New Brunswick, New Jersey
  • +1 more
Nov 16, 2022

Breast Cancer Trial in United Kingdom (Hydrogen Peroxide)

Recruiting
  • Breast Cancer
  • Hydrogen Peroxide
  • Lucknow, Uttar Pradesh, India
  • +7 more
Sep 21, 2022

Blood and Tumor Samples From Advanced or Metastatic Estrogen

Active, not recruiting
  • Advanced Breast Carcinoma
  • +8 more
  • Biopsy
  • +2 more
  • Scottsdale, Arizona
  • +2 more
Jan 3, 2023

Breast Cancer Trial in Tübingen

Recruiting
  • Breast Cancer
    • Tübingen, Baden-Württemberg, Germany
      University Hospital Tübingen, Department of Radiation Oncology
    May 5, 2021

    Metastatic Breast Cancer Trial in Worldwide (Ixabepilone Injection)

    Recruiting
    • Metastatic Breast Cancer
    • Ixabepilone Injection
    • Aalst, Belgium
    • +11 more
    Nov 28, 2022

    Cancer-related Fatigue Trial in Taipei (PG2 Lyo. Injection 500mg, Placebo 0.9% normal saline)

    Recruiting
    • Cancer-related Fatigue
    • PG2 Lyo. Injection 500mg
    • Placebo 0.9% normal saline
    • Taipei, Taiwan
      National Taiwan University Hospital
    Jun 27, 2022

    Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer Trial in London (Palbociclib, Avelumab)

    Recruiting
    • Triple Negative Breast Cancer
    • +5 more
    • Manchester, Greater Manchester, United Kingdom
    • +6 more
    Jan 5, 2023

    Triple-Negative Breast Cancer, Breast Cancer Trial in United States (Romidepsin, Cisplatin, Nivolumab)

    Active, not recruiting
    • Triple-Negative Breast Cancer
    • Breast Cancer
    • Fairway, Kansas
    • +6 more
    Nov 19, 2021

    Breast Cancer Female, Triple Negative and Androgen Receptor Positive Trial in Caen (Darolutamide, Capecitabine)

    Active, not recruiting
    • Breast Cancer Female
    • Triple Negative and Androgen Receptor Positive
    • Caen, France
      Centre François Baclesse
    Jan 3, 2022

    Breastcancer, Breast Tumor Trial in United States (SV-BR-1-GM, Cyclophosphamide, Interferon-alpha-2b)

    Completed
    Has Results
    • Breastcancer
    • Breast Neoplasm
    • SV-BR-1-GM
    • +2 more
    • Santa Rosa, California
    • +4 more
    Jan 27, 2021

    Advanced Breast Cancer Trial in China (Everolimus, Exemestane, Everolimus Placebo)

    Completed
    • Advanced Breast Cancer
    • Guangzhou, Guangdong, China
    • +14 more
    Jun 17, 2022

    Breast Cancer Trial in United States (Alpelisib, Sacituzumab govitecan)

    Recruiting
    • Breast Cancer
    • Fairway, Kansas
    • +6 more
    Apr 4, 2022

    Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma

    Recruiting
    • Anatomic Stage IV Breast Cancer AJCC v8
    • +20 more
    • Neoantigen Peptide Vaccine
    • +2 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Sep 7, 2022